Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients.

Hu, Bei; Lin, Xiao; Lee, Hans C; Huang, Xuelin; Tidwell, Rebecca S Slack; Ahn, Kwang Woo; Hu, Zhen-Huan; Jabbour, Elias; Verstovsek, Srdan; Ravandi, Farhad; Garcia-Manero, Guillermo; Kharfan-Dabaja, Mohamed A; Hossain, Nasheed M; Marks, David I; Kamble, Rammuriti T; Inamoto, Yoshihiro; Kindwall-Keller, Tamila; Saad, Ayman; Litzow, Mark R; Savani, Bipin N; ... (2020). Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leukemia & lymphoma, 61(12), pp. 2811-2820. Taylor & Francis 10.1080/10428194.2020.1783444

Full text not available from this repository. (Request a copy)

While TKI are the preferred first-line treatment for chronic phase (CP) CML, alloHCT remains an important consideration. The aim is to estimate residual life expectancy (RLE) for patients initially diagnosed with CP CML based on timing of alloHCT or continuation of TKI in various settings: CP1 CML, CP2 + [after transformation to accelerated phase (AP) or blast phase (BP)], AP, or BP. Non-transplant cohort included single-institution patients initiating TKI and switched TKI due to failure. CIBMTR transplant cohort included CML patients who underwent HLA sibling matched (MRD) or unrelated donor (MUD) alloHCT. AlloHCT appeared to shorten survival in CP1 CML with overall mortality hazard ratio (HR) for alloHCT of 2.4 (95% CI 1.2-4.9; p = .02). In BP CML, there was a trend toward higher survival with alloHCT; HR = 0.7 (0.5-1.1; p = .099). AlloHCT in CP2 + [HR = 2.0 (0.8-4.9), p = .13] and AP [HR = 1.1 (0.6-2.1); p = .80] is less clear and should be determined on a case-by-case basis.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Bacher, Vera Ulrike

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1042-8194

Publisher:

Taylor & Francis

Language:

English

Submitter:

Pierrette Durand Lüthi

Date Deposited:

05 Jan 2021 11:15

Last Modified:

05 Jan 2021 11:15

Publisher DOI:

10.1080/10428194.2020.1783444

PubMed ID:

32662346

Uncontrolled Keywords:

Chronic myeloid leukemia allogeneic stem cell transplant tyrosine kinase inhibitors

URI:

https://boris.unibe.ch/id/eprint/145310

Actions (login required)

Edit item Edit item
Provide Feedback